Quality Organic Standardized Medicinal Cannabis
Licensed since March 2014, ABcann sets itself apart from other Canadian licensed producers with its 94% customer retention rate, its focus on organic cultivation in proprietary growing chambers and its industry-leading production yields in excess of 250 grams per sq. ft., double the industry average. The company, which is in the process of developing its 65-acre site with a second 150K sq. ft. facility, has a research partnership with the University of Guelph and and has supplied innovative cannabis inhaler device maker Syqe Medical with its standardized cannabis.
An Exclusive Webinar
with ABcann CEO, Aaron Keay
ABcann Global is expected to begin trading publicly within the next several days with the symbol ABCN on the TSX Venture. New Cannabis Ventures Managing Partner Alan Brochstein hosted ABcann CEO Aaron Keay, who discussed the company as he reviewed its corporate presentation and then took questions. Download ABcann Medicinals Filing Statement.
Over 65 acres for growth – one of the largest in industry
The ABcann Advantage
Above Industry Average Yields
ABcann’s standardized organic growing methods yield not only a higher quality product as reflected by its premium pricing but also a lower overall cost. According to PI Financial, ABcann is able to produce almost double the industry average as measured by grams per square foot.
Experienced Management Team
Founder, Executive Chairman
Ken has been the key component and driving force behind ABcann’s development. His vison is unique in the medical cannabis sector with the concept of standardized production and dosage. Ken enjoys a strong rapport with Health Canada and numerous strategic partnerships worldwide. “I have only met briefly with Ken but anyone who is able to take an idea and with Pitbull determination transform it into a world class corporation like ABcann, in such a short time, is truly a miracle worker.” Dr. Mike Shannon, former Deputy Surgeon General Canada.
Chief Executive Officer
Aaron has spent the last 11 years working in the capital markets across a broad spectrum of sectors. Aaron’s roles have ranged from corporate finance, senior management and board member. He has overseen finance and M&A transactions and Capital raising, helping private companies navigate from the private to public markets. His work and leadership has helped raise ~$250m for public and private market issuers.
Chief Financial Officer
Jenny has been with ABcann since 2012 and is responsible for corporate financial reporting, operations, treasury, tax, budget planning, corporate policies, internal controls and ABcann’s relationship with external auditors. Coming from a business accounting background, she has over 15 years experience in various key leadership roles in business operations, finance, and program management.
Neil has over 30 years of experience in operating and managing businesses, in both the commercial development and recreational facilities market place, with annual revenues in excess of $6.5M. Neil serves as managing partner and CFO for this group of companies, which has over 200 employees.
VP, Business Development
Andrew LaCroix started his legal career working for blue chip firms in Vancouver, and has run his own practice on Vancouver Island since 2008. Andrew has been involved with ABcann since its inception as general counsel, drafting and submitting ABcann’s initial Health Canada license application and acting as general counsel on a host of different business and legal issues. Andrew will provide ABcann Global Corporation with ongoing advice, and play a large role in both domestic and international business development.
Former President and CEO of PARTEQ Innovations at Queen’s University for 28 years. His leadership led to the formation of 48 companies based on Queen’s research, with more than $1.7 billion invested to date in those companies.
Board of Directors
Mr Kramp was a Member of Parliament for the riding of Prince Edward-Hastings from 2004 through October of 2015. His past political experience includes six years as a municipal councilor and deputy reeve in the municipality of Madoc. Mr. Kramp brought vast experience in the private sector to his role. He has created and operated several successful business ventures in the fields of retail, wholesale and hospitality.
Board of Directors
Mr. Easson has over 23 years of experience advising companies on Corporate Finance, and Mergers and Acquisition transactions. Whether it be through his own BE Capital Advisors practice or his 15 years working for BMO, RBC and Scotiabank, John has significant transaction experience with a range of companies from small private start-ups to some of Canada’s largest public companies.
Board of Directors
Mr. Lucas served as President and CEO of GlaxoSmithKline Canada from 1994 until he retired in 2012. Currently Mr. Lucas is a member of the Board of Directors of RnA Diagnostics Inc and He is also Chair of the Board of EcoSynthetix Inc., Induran Ventures Inc., and Life Sciences Ontario. He received his BSc (Honours) in Biology and Chemistry from Queen’s University, and obtained his Chartered Directors designation (CDir) from the Directors College.
Strong Advisory Board Led by
the “Father of Cannabis Medicine”
Dr. Raphael Mechoulam is an Israeli organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel. Mechoulam is best known for his work (together with Y. Gaoni) in the isolation, structure elucidation and total synthesis of Δ9-tetrahydrocannabinol, the main active principle of cannabis and for the isolation and the identification of the endogenous cannabinoids anandamide from the brain and 2-arachidonoyl glycerol (2-AG) from peripheral organs together with his students, postdocs and collaborators.